Donor Lymphocyte Infusions (DLI): Guidelines ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Auteur(s) :
De Vos, John [Auteur]
Baudoux, Etienne [Auteur]
Bay, Jacques-Olivier [Auteur]
Calmels, Boris [Auteur]
Cras, Audrey [Auteur]
El Cheikh, Jean [Auteur]
Guerout-Verite, Marie-Agnes [Auteur]
Lacassagne, Marie-Noelle [Auteur]
Lamure, Sylvain [Auteur]
Letellier, Catherine [Auteur]
Menard, Anne-Lise [Auteur]
Daguindau, Etienne [Auteur]
Poire, Xavier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Guillaume, Thierry [Auteur]
Baudoux, Etienne [Auteur]
Bay, Jacques-Olivier [Auteur]
Calmels, Boris [Auteur]
Cras, Audrey [Auteur]
El Cheikh, Jean [Auteur]
Guerout-Verite, Marie-Agnes [Auteur]
Lacassagne, Marie-Noelle [Auteur]
Lamure, Sylvain [Auteur]
Letellier, Catherine [Auteur]
Menard, Anne-Lise [Auteur]
Daguindau, Etienne [Auteur]
Poire, Xavier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Guillaume, Thierry [Auteur]
Titre de la revue :
Bulletin du cancer
Nom court de la revue :
Bull Cancer
Date de publication :
2018-12-20
ISSN :
1769-6917
Mot(s)-clé(s) en anglais :
Cellular immunotherapy
Donor lymphocyte infusion
Allogeneic stem cell transplantation
Donor lymphocyte infusion
Allogeneic stem cell transplantation
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and ...
Lire la suite >Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.Lire moins >
Lire la suite >Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2019-10-22T08:16:38Z